Lipomics President a Guest Speaker at FDA’s Genomics and Proteomics Interest Group Meeting
News Oct 25, 2005
Lipomics Technologies, Inc. has announced that Steve Watkins, Ph.D., Lipomics founder, president, and chief scientific officer, was a guest speaker at the recent Genomics and Proteomics Interest Group meeting at the Food and Drug Administration (FDA).
Watkins’ presentation addressed metabolomics, focusing on small molecule metabolites that are proximal effectors of health and disease and hold considerable promise in many aspects of drug development and personalized medicine.
“The FDA is clearly thinking to the future by devoting a session of a group generally focused on genomics to the topic of metabolomics,” said Tom Anderson, Ph.D., Lipomics’ CEO.
“The FDA is looking ahead to applications of metabolomics in the drug development process and we are pleased that Steve was asked to provide the overview to this group.”
Chaired by Dr. Norris Alderson, the Associate Commissioner of Science at the FDA, this working group includes leading scientists at each of the seven centers of the FDA.
The Group meets periodically to enable FDA scientific leaders to stay current with the rapidly changing landscape of genomics and proteomics.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE